Introduction {#Sec1}
============

According to national and international guidelines, metformin is the recommended first-line oral therapy for the treatment of type 2 diabetes \[[@CR1]--[@CR3]\]. This is down to several factors, including the impressive safety record of the drug, having been in clinical use for over 50 years and the fact that metformin treatment is weight neutral. In addition, there are likely to be other beneficial effects, including a reduction in cardiovascular disease and mortality compared with non-intensive treatment \[[@CR4]\] and a possible reduction in cancer incidence, which has been seen in some \[[@CR5]--[@CR7]\], but not all \[[@CR8]\], studies. As metformin was discovered in the era before modern target-based drug discovery, the molecular details of its mechanism of action were not established before it was used clinically and these continue to be an area of vigorous research. In this review we discuss what is known and unknown about the molecular action of metformin.

Molecular action and target of metformin: lessons and insights from early studies {#Sec2}
=================================================================================

Chemically, biguanides such as metformin are composed of two guanidine groups joined together with the loss of ammonia. Anti-hyperglycaemic effects have been observed in response to many, but not all, guanidine-containing compounds. For metformin, these effects are uniquely dissociated from toxicity. Before the biguanides, attention was first focused on guanidine itself \[[@CR9]\], which was too toxic for clinical use, then diguanides (also known as synthalins or diguanidines) \[[@CR10]\], composed of two guanidines connected by an alkyl chain of variable length. Two diguanides, synthalin A and synthalin B, were used clinically, but marked toxicity, which could not be dissociated from therapeutic effects, was noted quite quickly \[[@CR11], [@CR12]\]. By the late 1950s, attention shifted to metformin and two other biguanides, phenformin and buformin. Even amongst these biguanides, metformin exhibits a superior safety profile. This is primarily because the risk of lactic acidosis, which can be fatal, is much higher for phenformin or buformin treatment \[[@CR13]\].

The large quantities of the drug required (up to 2.5 g per day) for therapeutic effects led early investigators to hypothesise that it might not depend on a conventional single/specific protein target. Early physiological studies on the diguanides found that reduced oxygen consumption accompanied hypoglycaemia \[[@CR14]\]. Later work found that guanidine \[[@CR15], [@CR16]\], diguanides \[[@CR16]\] and phenformin \[[@CR17], [@CR18]\] reduce mitochondrial oxygen consumption, suggesting that this organelle is an important site of action of guanidine-based agents. Several models have been proposed to account for these effects. The first model was based on observations that a common property of biguanides and other guanidines is to change the charge distribution and/or net charge of membranes \[[@CR19]\]. This work showed that these drugs could inhibit the transport of protons and other cations across membranes \[[@CR19]\]. However, the magnitude of these effects did not correlate well with anti-hyperglycaemic efficacy, with some ineffective drugs interacting with membranes much more readily than either phenformin or metformin \[[@CR20]\]. Furthermore, whilst phenformin has appreciable hydrophobicity and interacts with membranes, metformin is unusually hydrophilic for a drug and is unlikely to interact with membranes significantly. For this reason, metformin is understood to require transporters to cross membranes. Another suggestion during this period was that guanidine-containing drugs induce anti-hyperglycaemic effects by displacing calcium from proteins such as pyruvate kinase \[[@CR21]\]; however, as in the experiments on membranes, these effects occurred only at very high concentrations and hydrophobicity was an important determinant of potency. Thus, the IC~50~ by phenformin was 2.5 mmol/l, but the corresponding value for metformin was 275 mmol/l---far higher even than the non-specific cation tetramethylammonium \[[@CR22]\]. This suggests that the calcium-mobilising effects described are unlikely to contribute to the therapeutic action of metformin either. Whether or not calcium-mobilising or lipid effects contribute to the toxicity of guanidines such as phenformin has not been thoroughly investigated. It has recently been suggested that the effects of metformin on the mitochondria depend on a third non-protein effect---direct targeting of metal ions \[[@CR23]\]---which takes the form of an unusual electron delocalised planar ring structure, where square planar geometry replaces more conventional tetragonal geometry \[[@CR24]\]. The compelling evidence of direct binding of metformin to metal ions, including extensive crystallographic \[[@CR25]\] and spectroscopic analysis \[[@CR24], [@CR26]--[@CR28]\], contrasts with the paucity of evidence regarding direct binding of the drug to recognised metformin-regulated proteins. Further work is required to establish how the metal-binding properties of metformin enable it to mediate mitochondrial inhibition.

A second important physiological response to biguanides is reduced gluconeogenesis \[[@CR29]\]. Over time, studies on guanidine derivatives began to link inhibition of mitochondrial respiration with reduced gluconeogenesis \[[@CR30]\]; however, as already indicated, the poor correlation of the magnitudes of these effects for some drugs led others to conclude that mitochondrial effects were more likely to contribute towards side effects such as lactic acidosis rather than therapeutic effects \[[@CR19], [@CR21]\]. In the case of metformin, for example, there is often little impact on cellular ATP levels, even when using concentrations well above those likely to be achieved in vivo. These difficulties led to the suggestion that anti-hyperglycaemic effects might owe more to drug-specific mitochondrial effects superimposed upon the general mitochondrial responses to guanide-containing drugs already described \[[@CR19]\]. One such effect of metformin was found in 2000, in a study of its effects on electron transport, the mitochondrial oxygen-dependent process that couples the citric acid cycle to ATP production, providing the bulk of most cells' energy requirements (Fig. [1](#Fig1){ref-type="fig"}). Studies employing hepatocytes, mitochondria and freeze-clamped livers found that metformin's suppression of hepatic glucose output is accompanied by inhibition of complex I in the mitochondrial electron transport chain \[[@CR31], [@CR32]\]. One key piece of evidence implicating complex I as the site of metformin action was that the drug inhibited mitochondrial oxidation of glutamate and malate more effectively than succinate \[[@CR31], [@CR32]\], which as a complex II substrate, can bypass complex I inhibition. Similar observations had been made earlier using other guanide-containing drugs \[[@CR15], [@CR16]\]; however, our understanding of mitochondrial respiration was probably insufficiently developed to allow this interpretation of the results at the time. Taken together, these studies provide compelling evidence of a correlation between inhibition of electron transport and glucose output. It should be noted, however, that it has not yet been possible to confirm in genetic experiments whether or not complex I is the only mitochondrial target of metformin. For example, it may be significant that recent studies have found that effects of metformin on mitochondrial respiration vary between cells, but more work is required to understand the underlying reason(s) for these variations \[[@CR33]\].Fig. 1(**a**, **b**) Schematic diagram of the anti-hyperglycaemic action of metformin on the liver cell. Part (**b**) shows a simplified version of (**a**). Metformin is transported into hepatocytes mainly via OCT1, resulting in an inhibition of the mitochondrial respiratory chain (complex I) through a currently unknown mechanism(s). The resulting deficit in energy production is balanced by reducing the consumption of energy in the cell, particularly reduced gluconeogenesis in the liver. This is mediated in two main ways. First, a decrease in ATP and a concomitant increase in AMP concentration occur, which is thought to contribute to the inhibition of gluconeogenesis directly (because of the energy/ATP deficit). Second, increased AMP levels function as a key signalling mediator that has been proposed to (1) allosterically inhibit cAMP--PKA signalling through suppression of adenylate cyclase, (2) allosterically inhibit FBPase, a key gluconeogenic enzyme, and (3) activates AMPK. This leads to inhibition of gluconeogenesis (1 and 2) and lipid/cholesterol synthesis (3), which may contribute to the longer term metabolic and therapeutic responses to the drug. FBPase; fructose-1,6-bisphosphatase

Studies on mitochondrial responses to metformin have reported that the magnitude of inhibition of gluconeogenesis is correlated to the extent of inhibition of the respiratory chain \[[@CR31]\]. This suggests that metformin-dependent cellular energy depletion results in insufficient flux of ATP required to drive energy-consuming hepatic gluconeogenesis (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR31]\]. ATP-/ADP-/AMP-independent effects on pyruvate carboxylase and other enzymes may also contribute to the inhibition of gluconeogenesis accompanying mild mitochondrial inhibition \[[@CR31], [@CR34]\]. Mitochondrial inhibition also provides a plausible explanation of lactic acidosis in metformin use, as lactate accumulation from glycolysis would be predicted to follow respiratory chain inhibition. Compared with phenformin and buformin, lactic acidosis is very much less common with metformin therapy \[[@CR35]--[@CR37]\]. This might be because metformin-dependent mitochondrial inhibition is understood to be self-limiting as it depends on the mitochondria being active \[[@CR31]\]. This property might also explain why metformin is very much less toxic than other complex I inhibitors, including the neurotoxic pesticide rotenone \[[@CR31]\]. Interestingly, thiazolidinediones, another class of drugs used for the treatment of type 2 diabetes, are also mild inhibitors of complex I, and this might contribute to their anti-hyperglycaemic effect \[[@CR38]\].

LKB1--AMPK-dependent pathway as a key molecular effector of metformin {#Sec3}
=====================================================================

A key study by Zhou et al in 2001 reported a 'modern' signal transduction effect of metformin on 5\' AMP-activated protein kinase (AMPK) \[[@CR39]\] (Fig. [1](#Fig1){ref-type="fig"}). AMPK is a critical cellular energy sensor and regulator of energy homeostasis \[[@CR40]\]. AMPK is activated by energy stresses that increase cellular ADP:ATP and/or AMP:ATP ratios, either by decreasing the catabolic production of ATP (e.g. via nutrient deprivation and exposure to mitochondrial toxins) or by promoting ATP consumption (e.g. by muscle contraction). Zhou et al \[[@CR39]\] hypothesised that AMPK might be an important molecular effector, as (1) metformin causes a reduction in cellular ATP:ADP ratios in hepatocytes \[[@CR31], [@CR32]\]; and (2) downstream effects of AMPK activation (e.g. promotion of glucose uptake and fatty acid oxidation in muscle, inhibition of lipid synthesis in the liver \[[@CR41]\]) simulate the therapeutic effects of metformin. They demonstrated that metformin indeed stimulates AMPK, and this stimulation is associated with inhibition of glucose production in rat primary hepatocytes. They also showed that metformin treatment decreases levels of sterol regulatory element-binding protein-1 (SREBP-1), a key lipogenic transcription factor, at both the mRNA and protein level in hepatocytes and liver tissue \[[@CR39]\]. In addition, they reported that metformin increases fatty acid oxidation in hepatocytes, although oral ingestion of metformin resulted in suppression of whole body lipid oxidation as well as inhibition of hepatic glucose production in humans \[[@CR42]\]. To demonstrate that the observed effects of metformin are sensitive to changes in the AMPK-dependent pathway, Zhou et al used a novel small molecule AMPK inhibitor named compound C. When rat primary hepatocytes were incubated with compound C, metformin-induced inhibition of acetyl-CoA carboxylase (a well known target of AMPK involved in lipid metabolism) and inhibition of glucagon-induced glucose production were significantly attenuated \[[@CR39]\]. However, it should be noted that several recent publications have shown that, in addition to AMPK, compound C potently and non-selectively inhibits numerous other protein kinases and therefore the results obtained using compound C are not conclusive \[[@CR43], [@CR44]\]. It has been shown that metformin does not directly target AMPK or affect its phosphorylation by upstream kinases (and phosphatases) in cell-free systems. A recent study has provided compelling evidence that it activates AMPK in an indirect manner via an increase in AMP:ATP and ADP:ATP ratios using an engineered cell line expressing AMPK complexes bearing either the wild-type γ2 isoform or Arg531 → Gly mutation that renders γ2 complexes insensitive to the effects of ADP and AMP on phosphorylation \[[@CR33]\].

The proposed key role for AMPK in mediating metformin action was further followed up by Shaw et al in 2005. They sought to determine the role of tumour suppressor protein LKB1, an upstream kinase of AMPK, in the liver and generated a liver-specific *Lkb1* (also known as *Stk11*) knockout mouse model \[[@CR45]\]. They found that metformin-induced AMPK activation was profoundly reduced in *Lkb1* knockout liver and that, strikingly, metformin treatment failed to produce a glucose-lowering effect in liver-specific *Lkb1* knockout mice rendered hyperglycaemic (by feeding these mice a fat-enriched diet). Shaw et al proposed that the LKB1--AMPK signalling controls the expression of key gluconeogenic genes via the regulation of a transcription coactivator \[[@CR45]\], namely, cAMP response element-binding protein-regulated transcription coactivator 2 (CRTC2) \[[@CR46]\]. In the fasting state, CRTC2 is in a dephosphorylated state and is localised in the nucleus where it enhances the transcriptional activation of the gluconeogenic genes, including those encoding peroxisome proliferator-activated receptor-γ coactivator-1α (*Ppargc1a*) and its subsequent gluconeogenic targets such as phosphoenolpyruvate carboxykinase (*Pck1*) and glucose-6 phosphatase (*G6pc*). Feeding (insulin) is thought to switch off glucose production (at least partially) through inhibition of gluconeogenic gene programmes via Akt kinase-signalling-dependent phosphorylation and cytoplasmic sequestration of CRTC2 and forkhead box O1 (FOXO1) proteins \[[@CR47]\]. Interestingly, metformin can also switch off gluconeogenesis independently of insulin/Akt signalling via LKB1--AMPK pathway. Consistent with this model, in fasted liver-specific *Lkb1* knockout mice, CRTC2 was localised predominantly in the nucleus, which was associated with increases in *Ppargc1a* and *G6pc* gene expression, as well as blood glucose levels compared with control mice \[[@CR45]\].

To establish whether the effects of metformin on glucoeneogenesis in the liver are mainly mediated through AMPK or LKB1-dependent kinases (other than AMPK), Foretz et al \[[@CR48]\] recently generated and examined two mouse models in which genes encoding the AMPKα1 and α2 catalytic subunits (*Prkaa1/2*) or LKB1 are knocked out specifically in hepatocytes. Interestingly, they showed that the administration of a bolus injection of metformin to hepatocyte-specific *Prkaa1/2* knockout mice resulted in a glucose-lowering effect comparable with that observed in control mice. In addition, treatment of primary hepatocytes lacking AMPK with metformin displayed a robust inhibition of glucose production (induced via the membrane-permeable cAMP analogue dibutyryl cAMP, which mimics the action of glucagon) and, in fact, the magnitude of inhibition was even greater than that observed in control wild-type hepatocytes \[[@CR48]\]. Consistent with the observation that liver-specific *Lkb1* knockout mice display higher blood glucose levels in the fasting state \[[@CR45]\], Foretz et al reported that *Lkb1*^−/−^ hepatocytes have higher rates of basal/unstimulated and cAMP-stimulated glucose production compared with *Lkb1*^+/+^ cells. However, unexpectedly, Foretz et al demonstrated that metformin inhibits glucose production normally in *Lkb1* knockout hepatocytes \[[@CR48]\]. One potential explanation for this discrepancy is that Shaw et al did not assess the immediate effect of metformin administration on hepatic glucose output by their liver-specific *Lkb1* knockout mice, either in vivo or in vitro (primary hepatocytes) \[[@CR45]\]. Instead, they reported that the protective effect of metformin against hyperglycaemia in response to the fat-enriched diet was eliminated by repeated administration (daily injection) of metformin in liver-specific *Lkb1* knockout mice. Thus, it can be speculated that, in the study of Shaw et al, metformin did not act directly to suppress glucose production but, rather, might have acted indirectly to protect the hepatocytes from high-fat diet-induced lipotoxicity and associated insulin resistance through suppression of lipid synthesis/lipogenic gene expression (Fig. [1](#Fig1){ref-type="fig"}). Finally, it should be noted that, although the mouse genetic model is a useful tool, inactivation of critical metabolic gene(s) could possibly result in compensatory adaptations in alternative pathway(s) to maintain glucose homeostasis and, in addition, results from mouse studies are not always applicable to human physiology and pathology. To date, there is no literature reporting that patients who have a poor glycaemic response to metformin have impaired AMPK signalling. There are many loss-of-function mutations of LKB1 associated with Peutz--Jeghers cancer syndrome \[[@CR49]\]; however, to the best of our knowledge, these patients have not been found to have a higher incidence of developing metabolic syndromes such as type 2 diabetes or insulin resistance, and *Lkb1* variants have not convincingly been reported to play a role in the glycaemic response to metformin in type 2 diabetes.

The liver is the main site of action of metformin: the role of organic cation transporters {#Sec4}
==========================================================================================

Metformin is not metabolised and is excreted in the urine and bile in an unmodified form. The pharmacokinetics of metformin are largely determined by its active transport by key organic cation transporters. Members of this transporter family \[[@CR50]\] are involved in active transport across the gut epithelium and hence determine rates of absorption (plasma membrane monoamine transporter \[PMAT\] and organic cation transporter \[OCT\] 3), they transport metformin into hepatocytes (OCT1) and from hepatocytes into the bile (multidrug and toxic compound extrusion \[MATE\] 1) and, finally, into the renal tubular epithelial cells (OCT2) and into the renal tubule (MATE2) \[[@CR51]\]. *Oct1* (also known as *Slc22a1*) knockout mice display reduced efficacy of metformin \[[@CR52]\] and this work has established an important role for OCT1 in metformin intake and reinforces the critical role of the liver as the primary site of action for metformin.

Although metformin exerts its major effect through inhibition of hepatic glucose production, enhanced glucose disposal has also been described. Some early studies suggested that metformin exerts its insulin-sensitising effect \[[@CR53]\] and/or promotes glucose transport independently of the insulin receptor-mediated proximal signalling pathway in skeletal muscle \[[@CR39], [@CR54], [@CR55]\]. Even though metformin may accumulate in skeletal muscle and other organs/tissues over longer periods of time to bring about some effects \[[@CR56]\], the concentration of metformin that was required to acutely stimulate AMPK and glucose transport in isolated rodent muscle tissue ex vivo \[[@CR39]\] or in cultured muscle cells \[[@CR54]\] was at least two orders of magnitude greater (typically used at ∼1--2 mmol/l and treated for 3--16 h) than those seen in plasma following the administration of therapeutic doses (mean plasma concentration of 4.5 μmol/l) \[[@CR57], [@CR58]\], making it unlikely that metformin has a major therapeutic effect in the muscle. The potent and preferential effects of metformin in the liver can be explained by the fact that the drug is supplied directly from the gut (via the portal vein), which means that a profoundly higher concentration of metformin (when taken orally) reaches the liver than other peripheral organs/tissues \[[@CR59]\], and by the high level of expression of OCT1, which actively transports metformin to its site of action, in hepatocytes. Metformin has also been reported to have a protective effect on the vascular endothelium, possibly explaining the potential cardiovascular benefit of this drug. This might reflect an indirect benefit owing to a reduction in hepatic glucose output and circulating insulin, but might also reflect a direct action of metformin on vascular endothelial cells, possibly activating AMPK and thereby increasing nitric oxide synthesis \[[@CR60], [@CR61]\] and decreasing reactive oxygen species through inhibition of complex 1 \[[@CR62]\].

Familiar and novel AMPK-independent mechanisms {#Sec5}
==============================================

The mouse genetic study demonstrating that AMPK is not required for the anti-hyperglycaemic action of metformin \[[@CR48]\] has led to proposals of AMPK-independent mechanisms that may account for the therapeutic effect of metformin. In the study of Foretz et al \[[@CR48]\], two pharmacological AMPK activators were used: (1) A-769662, which allosterically stimulates AMPK independently of canonical AMP-binding sites located in the cystathionine β-synthase (CBS) domain of the regulatory γ-subunit \[[@CR63], [@CR64]\], and (2) 5-aminoimidazole-4-carboxamide-1-β-[d]{.smallcaps}-ribofuranoside (AICAR), an AMP mimetic. The authors demonstrated that the former failed to elicit a significant inhibitory effect on glucose output, but the latter profoundly suppressed glucose output in hepatocytes isolated from *Prkaa1/2* (AMPK) knockout animals \[[@CR48]\], indicating AMP per se but not the AMPK enzyme may play a vital role in modulating (inhibiting) hepatic glucose output \[[@CR50]\]. They also demonstrated that metformin elicited a decrease in ATP and a concomitant rise in AMP levels, and found that there was a tight correlation between the magnitude of ATP reduction and inhibition of glucose output. Gluconeogenesis is an energy-consuming process (requires six molecules of ATP per molecule of glucose generated); thus, hepatocytes would be forced to balance energy demand with generation under conditions of energy stress \[[@CR65]\]. Previous work showed the exquisite control that energy charge can exert over gluconeogenic flux through allosteric regulation of key metabolic enzymes in this pathway. For example, AMP suppresses the gluconeogenic enzyme fructose-1,6-bisphosphatase \[[@CR66]\]. Taken together, these results indicate that the mitochondrial effects of the drug, which are upstream of effects of AMPK and therefore independent of the kinase, might contribute directly to the flux control of gluconeogenesis \[[@CR31]\].

Interestingly, a more recent study has found evidence for AMPK-independent effects of mitochondrial inhibition on a canonical signal transduction system that controls hepatic gluconeogenesis. Miller et al \[[@CR67]\] found that metformin and its sister drug phenformin antagonise effects of the counter-regulatory hormone glucagon on adenylate cyclase, attenuating glucagon-dependent increases in cAMP levels and concomitant activation of the cAMP-dependent protein kinase (known as protein kinase A \[PKA\]) signalling pathway. As discussed above, this is the critical signalling node controlling the gluconeogenic programme during fasting \[[@CR47]\]. These interesting findings build upon earlier reports that metformin regulates glucagon-dependent cAMP signalling \[[@CR68]--[@CR70]\]. Phenformin blocked glucagon-induced cAMP accumulation in AMPK-deficient hepatocytes, demonstrating that this effect is AMPK-independent. Phenformin inhibited glucagon-stimulated PKA target phosphorylation but did not block responses to a membrane-permeable non-hydrolysable analogue of cAMP, thus verifying that the reductions in cellular levels of endogenous cAMP are important for the actions of phenformin. The net concentration of cAMP can be modulated by synthesis or degradation (or a combination of the two), which are regulated by adenylate cyclase and phosphodiesterase, respectively. Specificity and compartmentalisation of this cAMP signalling pathway is commonly mediated by the multiplicity of G-protein-coupled receptors, G-proteins and phosphodiesterases \[[@CR71]\], but these were each excluded in turn from playing a role in the effects of biguanides \[[@CR67]\]. Phosphodiesterases were excluded on the basis that pharmacological inhibition of these enzymes did not prevent the ability of phenformin to reduce cAMP levels \[[@CR67]\]. An action of biguanides at the level of G-proteins or G-protein-coupled receptors was ruled out on the basis that phenformin reversed cAMP elevation in response to forskolin \[[@CR67]\], which activates adenylate cyclase directly. Miller et al instead suggest that the incubation of cells with phenformin leads to inhibition of adenylate cyclase. This action of phenformin is indirect, as it depends on mitochondrial inhibition elevating cellular AMP concentrations. If this is the case, then how does AMP switch off cAMP elevation in cells? Miller et al propose that AMP directly binds to an inhibitory site on adenylate cyclase called the 'P-site'. It is worth noting that although there are several P-site ligands (including adenine, deoxy-adenosine phosphate and AMP), the physiological/pharmacological relevance of this regulatory event had been elusive.

Further work will be required to establish to what extent these effects of phenformin may be extrapolated to metformin. It may be significant, for example, that the targeting of glucagon signalling does not readily account for the lack of hypoglycaemia experienced in response to metformin use. In this respect, metformin differs from glucagon receptor knockouts and antagonists, where hypoglycaemic episodes have been observed \[[@CR72]--[@CR74]\]. An additional important focus of further work will be to investigate how targeting of adenylate cyclase enables biguanides to specifically antagonise glucagon without affecting signalling through other cAMP signalling pathways. To take just one important example, in clinical use, metformin is not thought to directly affect cardiovascular variables such as blood pressure \[[@CR75]\]. The pharmacokinetics of metformin, which is predominantly targeted to the liver, might help to account for this to some extent. On the other hand, if some of the effects on cAMP signalling are found to be restricted to phenformin, these could account for the cardiovascular side effects that were a hallmark of the clinical experience of phenformin and which ultimately contributed to its withdrawal \[[@CR76], [@CR77]\]. Finally, earlier work has noted responses to modest concentrations of metformin even in the presence of hydrolysis-resistant forms of cAMP \[[@CR48]\]. Thus, the relative contributions of cAMP-dependent and cAMP-independent hepatic effects of metformin will need to be gauged carefully by further studies.

Conclusion and clinical perspective {#Sec6}
===================================

After over 50 years of using metformin for the treatment of type 2 diabetes we continue to learn about how this safe and effective treatment works. Whilst this in itself is of considerable biological value, it also starts to pave the way towards a more targeted approach to therapy and novel drug development. The most widely accepted model of the anti-hyperglycaemic action of metformin is that suppression of hepatic gluconeogenesis occurs principally as a consequence of mitochondrial inhibition. AMPK, which is activated in response to mitochondrial inhibitors, including metformin, has been proposed to be an important effector of metformin. However, the most recent mouse genetic studies indicate that suppression of gluconeogenesis may depend more directly on the mitochondrial respiration rate \[[@CR48], [@CR78]\], as was originally proposed \[[@CR31]\], and/or on AMPK-independent cellular responses to reductions in ATP availability, such as the recently described effects on cAMP-PKA signalling \[[@CR67]\]. In addition, it should be noted that AMPK might play a key role in long-term effects of metformin by improving lipid metabolism and mitochondrial function in the liver. From the recent insights into the mechanisms of metformin highlighted in this review, it can be seen that we are finally moving towards understanding the molecular mechanism of metformin. But what are the clinical implications of these novel insights? First, we can start to see how understanding the molecular mechanism can lead to a more targeted approach to therapy using existing drugs. Second, these novel mechanisms may point towards druggable targets, allowing the development of novel diabetes therapies.

The glycaemic response to metformin is highly variable, even after controlling for differences in adherence to medication. Given the key role of the organic cation transporters in metformin distribution, these are an area of ongoing exploration, with a number of loss-of-function genetic variants described in *OCT1* and *OCT2*. For example, Shu et al identified several polymorphisms of *OCT1* that displayed a reduced uptake of metformin when ectopically overexpressed in cultured cells \[[@CR52]\]. In this study, a few variants such as OCT1-Arg61Cys exhibited a reduced plasma membrane and enhanced cytosolic localisation compared with the reference OCT1. In some \[[@CR52], [@CR79], [@CR80]\], but not all \[[@CR81]\], studies, non-diabetic or diabetic patients carrying these loss-of-function variants in *OCT1* did not respond to metformin. More work is required to establish whether these affect more than the glycaemic response (e.g. vascular, cardiovascular and cancer benefits), and definitive genotype stratified clinical trials are required, but it may not be too long before patients who are not likely to respond to metformin on the basis of their genotype are offered an alternative first-line therapy. What about other aspects of pharmacogenetics? Non-candidate gene approaches recently revealed a robustly replicated locus associated with the response to metformin on chromosome 11 \[[@CR51], [@CR82], [@CR83]\], with subsequent follow-up work pointing to the *Npat* and *Atm* genes as the likely causal genes (E. R. Pearson, R. McCrimmon, M. McCarthy, unpublished data). Future candidate gene studies focusing on genes involved in copper transport and exchange, oxidative phosphorylation and the glucagon/cAMP signalling pathway will establish their contribution to the therapeutic benefit of metformin. Ongoing work in this area should provide more insight into the molecular mechanism of metformin and greater potential for targeted therapy.

What about new drugs? At first sight, the impressive safety profile and low cost of metformin itself might discourage pharmaceutical companies from developing drugs that act in a similar manner. It should be noted, however, that the drug is sometimes associated with uncomfortable gastrointestinal side effects, contributing to the non-compliance observed in perhaps as many as one-third of patients initially prescribed it \[[@CR84]\]. In addition, type 2 diabetes is a progressive disorder that necessitates additional medication following failure of metformin monotherapy \[[@CR1]\]. Progress in establishing the identity of the clinically important target(s) and key effectors of metformin will ultimately enable rational target-based design of more potent or better-tolerated drugs to support metformin use. For example, if post-glucagon receptor modification of glucagon signalling, as reported by Miller et al for phenformin treatment in rodents \[[@CR67]\], can be shown to be an important effector of metformin therapy in humans, the allosteric inhibitor P-site on adenylate cyclase provides an alternative approach to blocking the receptor itself, and this offers an intriguing novel mechanism for inhibiting glucagon action in the liver. There are glucagon receptor antagonists in development and these offer promise as potential therapeutic agents \[[@CR73]\]. However, there is some concern that direct blockade of the receptor may result in islet hyperplasia, as seen in rodents in which the glucagon receptor has been knocked out \[[@CR72]\]. Additionally, increases in serum cholesterol and transaminases have been reported for glucagon receptor antagonists in clinical trial; effects not seen with metformin \[[@CR85]\]. Whether this reflects its post-glucagon receptor action or other mechanisms of metformin is unclear. An alternative approach based on work on the metal-binding properties of metformin would be to develop agents capable of directly targeting copper ion transport or exchange. Type 2 diabetes is known to be accompanied by altered copper handling \[[@CR86], [@CR87]\], and work with other drugs has already demonstrated that drug-based copper sequestration ameliorates diabetes-related cardiovascular disease, independently of effects on glycaemia \[[@CR88], [@CR89]\]. Consequently, it will be interesting to study the role of copper binding in the cardioprotective effects of metformin itself.
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